SLFN11 overexpression correlates with PARP inhibitor sensitivity, as shown in SCLC PDXs treated with olaparib or talazoparib, as well as in SCLC patients treated with veliparib in combination with temozolomide (Allison Stewart et al. 2017; Lok et al. 2017). Here, PARP1 is linked to small cell lung carcinoma.